Table 2.
Difference of features between PNI (-) or (+) in development and validation cohort
| Characteristics | Development cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| PNI ( - ) | PNI ( + ) | P value | PNI ( - ) | PNI ( + ) | P value | |
| N = 228 | N = 71 | N = 91 | N = 36 | |||
| Age (y) | 60.1 ± 11.8 | 59.0 ± 13.7 | 0.571 | 61.1 ± 13.3 | 61.0 ± 15.6 | 0.990 |
| Gender | 1.000 | 0.942 | ||||
| Male (%) | 133 (58.3%) | 42 (59.2%) | 58 (63.7%) | 22 (61.1%) | ||
| Female (%) | 95 (41.7%) | 29 (40.8%) | 33 (36.3%) | 14 (38.9%) | ||
| Location | 0.229 | 0.447 | ||||
| Ileocecal (%) | 2 (0.88%) | 1 (1.41%) | 1 (1.10%) | 1 (2.78%) | ||
| Ascending (%) | 62 (27.2%) | 19 (26.8%) | 16 (17.6%) | 11 (30.6%) | ||
| Transverse (%) | 17 (7.46%) | 11 (15.5%) | 11 (12.1%) | 3 (8.33%) | ||
| Descending (%) | 25 (11.0%) | 9 (12.7%) | 12 (13.2%) | 4 (11.1%) | ||
| Sigmoid (%) | 122 (53.5%) | 31 (43.7%) | 51 (56.0%) | 17 (47.2%) | ||
| CA199 (U/mL) | 53.3 ± 213 | 371 ± 1595 | 0.099 | 69.0 ± 418 | 257 ± 859 | 0.216 |
| CEA (ng/mL) | 12.8 ± 21.8 | 123 ± 582 | 0.116 | 259 ± 2345 | 119 ± 340 | 0.578 |
| AFP (ng/mL) | 3.33 ± 7.96 | 2.87 ± 1.30 | 0.400 | 2.54 ± 1.18) | 2.61 ± 1.08 | 0.762 |
| CA125 (U/mL) | 17.3 ± 22.3 | 32.5 ± 39.6 | 0.003 | 19.7 ± 32.6 | 28.4 ± 43.5 | 0.286 |
| T stage | 0.004 | 0.481 | ||||
| T2-T3 (%) | 152 (66.7%) | 33 (46.5%) | 56 (61.5%) | 19 (52.8%) | ||
| T4 (%) | 76 (33.3%) | 38 (53.5%) | 35 (38.5%) | 17 (47.2%) | ||
| N stage | <0.001 | 0.060 | ||||
| N0 (%) | 102 (44.7%) | 11 (15.5%) | 41 (45.1%) | 9 (25.0%) | ||
| N1-N2 (%) | 126 (55.3%) | 60 (84.5%) | 50 (54.9%) | 27 (75.0%) | ||
| Differentiation | 0.002 | 0.058 | ||||
| Low (%) | 24 (10.5%) | 17 (23.9%) | 9 (9.89%) | 7 (19.4%) | ||
| Middle (%) | 189 (82.9%) | 54 (76.1%) | 74 (81.3%) | 29 (80.6%) | ||
| High (%) | 15 (6.58%) | 0 (0.00%) | 8(8.79%) | 0 (0.00%) | ||
| Radio-score | 0.20 ± 0.13 | 0.41 ± 0.19 | <0.001 | 0.21 ± 0.13 | 0.46 ± 0.15 | <0.001 |
Radio-score, the likelihood of PNI occurrence in stage II-III colon cancer